Long-term adherence to a prescribed low-sodium diet is poor in heart-failure patients, the population where the medical case for restriction is unambiguous, where adherence is professionally counseled, and where the cost of exceeding the limit is hospitalization. Chung et al.’s peer-reviewed cohort documents this directly: patients classified as non-adherent excreted about 4,135 mg of sodium per day on objective 24-hour urinary measurement versus about 3,086 mg among adherent patients. Pooled objective-adherence rates across this broader literature run roughly 20-40%, implying that the majority exceed their limit; we take a ~70% lapse rate as the action-side proxy midpoint, not a figure reported by any single study. That proxy is used because no published study asks “do you regret going on a low-sodium diet?” head-on. Healthy US adults attempting voluntary reduction without clinical pressure almost certainly lapse at higher rates, not lower. Lapsing is not regretting: some lapsed because food became unpalatable, some because of social and family meals, some because they concluded the benefit was not worth the sacrifice. The He, Li & MacGregor 2013 Cochrane meta-analysis in BMJ — 34 trials, 3,230 participants — established that modest salt reduction lowers systolic blood pressure by 5.39 mm Hg in hypertensives and 2.42 mm Hg in normotensives, so the intervention itself delivers real (if modest) benefits when sustained.
On the other side, 47.7% of US adults have hypertension per CDC NCHS Data Brief No. 511 (Oct 2024), based on NHANES August 2021
- August 2023 measurement data — a downstream clinical state that excess sodium intake partly causes, used here as the inaction-side proxy. This figure also falls short of a direct regret measure: many of the 47.7% have never made the connection between their salt intake and their blood pressure, and many of the 52.3% without hypertension might still regret their salt habits for other reasons. Hypertension has multiple causes (genetics, age, weight, alcohol, sodium, physical activity); sodium is one contributor among several. The two figures come from different instruments (clinical adherence cohort vs federal surveillance survey) and measure different constructs (behavioral abandonment of a prescribed regimen vs current clinical state), so the apparent 1.5:1 action-to-inaction ratio overstates the precision of the cross-side comparison. The American Heart Association’s standing dietary guidance — no more than 2,300 mg/day with an ideal target of 1,500 mg/day — sits well below the measured average US intake of roughly 3,400 mg per day.
The SSaSS NEJM 2021 cluster trial of 20,995 rural Chinese adults provides the strongest hard-endpoint evidence on the inaction side: switching from regular salt to a potassium-enriched substitute reduced stroke by 14%, major cardiovascular events by 13%, and all-cause death by 12% over 4.7 years. The Mente et al. 2016 Lancet pooled analysis of PURE and three other cohort studies (133,118 adults, 49 countries) reported a U-shaped association with apparent excess cardiovascular risk below ~3,000 mg sodium per day — that finding is contested for methodological reasons (single-spot urine with the Kawasaki formula) and is not currently reflected in the AHA or WHO guidelines, but it is the cleanest published basis for the J-curve concern at the lowest intake range. The action-dominates pattern reflects the asymmetry between a very high prescribed-diet lapse rate and a substantial but lower share of US adults already living with the downstream condition the diet is meant to prevent. Both figures are proxies for different constructs (behavioral abandonment vs current clinical state), so the delta should be read with caution.